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A recombinant plasmid carrying the long terminal repeat 
(LTR) of the human immunodeficiency virus 1 (HIV-1) 
linked to the reporter chloramphenicol acetyl transferase 
(CAT) gene was stably introduced into human fibroblasts. 
The transfectant cells expressed CAT activity from the 
HIV LTR. The response to anti-neoplastic drugs, i.e. 
cisplatin, a platin derivative, and hexadecylphosphocho-
line, was studied. It was found that at 5 χ 10 G M 
concentrations cisplatin stimulates by 2.2-fold the 
expression of CAT from the HIV LTR. Our results extend 
our observations on the effect of cisplatin on HIV LTR in 
rodent fibroblast cells and suggest caution against 
therapy including cisplatin in the treatment of AIDS 
patients. 
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Introduction 
The discovery in 19691 that cisplatin has antitumor 
activity has led to the use of this compound in the 
chemotherapy of several types of human tumors 
(for a review see ref. 2). Although the site of action 
of cisplatin is not certain it is thought that DNA is 
the critical target.3 
The human immunodeficiency virus (HIV) is the 
causative agent of the acquired immune deficiency 
syndrome (AIDS) (for a review see ref. 4). AIDS 
patients are at increased risk from a variety of 
cancers, including Kaposi's sarcoma, non-Hodg-
kin's lymphoma, squamous cell carcinoma, testicu­
lar cancers, malignant melanoma, primary hepato­
cellular carcinoma and Hodgkin's disease.4 
The HIV-1 LTR contains a variety of regulatory 
sequences (for a review see ref. 5). We have 
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previously shown that cisplatin transcriptionally 
activates the HIV LTR sequences in rat fibroblasts.6 
In the present study we have examined the effect of 
cisplatin on the HIV LTR in human fibroblasts and 
found that cisplatin also stimulates transcriptional 
activation significantly in this system. 
Materials and methods 
R e c o m b i n a n t p l a s m i d s and cel l l ines 
Plasmid pBHIVl was derived from plasmid 
pBC12/HIV/CAT7 by inserting a 1.9 kb BamHl 
fragment carrying the aph gene into the single 
BamHl site. Plasmid pBC12/HIV/CAT carries a 728 
bp Xhol-Hindlll DNA fragment containing the 
HIV LTR sequences linked to the CAT reporter 
gene. 
The MRCSV40TGR human fibroblasts were 
obtained after immortalization of MRC cells 
with SV40 and are resistant to 6-thioguanine. 
SVTGHIV1-1 cells were obtained after transfec-
tion with plasmid pBHIVl and selection in the 
presence of geneticin. 
CAT a s s a y s 
Cells were grown exponentially in Ham's medium 
containing 10% fetal calf serum and assayed for 
CAT activity as previously described.8 
Assay for cel l p r o l i f e r a t i o n 
The rapid colorimetrie assay for cell proliferation 
of Mossmann9 was used as previously described.6 
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Results 
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Figure 1. Induction of CAT activity by cisplatin. (a) 
Chromatogram of representative CAT assay with extracts 
from recipient MRCSV40TGR and transfectant SVTGHIV1-
1 cells with and without treatment with cisplatin. (b) 
Histogram of recorded CAT activities. MRCSV40TGR and 
SVTGHIV1-1 cells were plated at 1.5 χ 106 cells/75 cm 2 
flask in Ham's SF12 medium containing 10% FCS at 37°C. 
24 h later the medium was replaced with Ham's 
SF12 medium containing 0.5% FCS and left for 
another 24 h at 37°C. The medium was then changed with 
Ham's SF12 containing 5% FCS and the varying 
concentrations of cisplatin. Cells were harvested 24 h 
later and tested for CAT activity as described in Materials 
and methods. Relative values of CAT activity in 
SVTGHIV1-1 cells were 48 pmole acetylated chlor­
amphenicol//^ protein per hour incubation. Average from 
three experiments is given. Standard deviation was less 
than 5% of the average values. 
Cisplat in e n h a n c e s t r a n s c r i p t i o n f r o m 
the HIV L.TR s e q u e n c e s 
The recipient MRCSV40TGR and the transfectant 
SVTGHIV1-1 cells were treated with cisplatin at 
various concentrations. A representative CAT assay 
is shown in Figure 1(a) and the corresponding 
histogram in Figure 1(b). Optimal stimulation was 
obtained at 5 x 10" 5 M, where CAT activity 
increased 2.2-fold. As shown in Figure 2 a time 
course revealed that 24 h exposure to cisplatin gave 
rise to maximal activation. 
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Figure 2. Induction of CAT activity in SVTGHIV1-1 
cells by cisplatin at various times post-treatment, 
(a) Chromatogram for representative CAT assays 
with extracts from SVTGHIV1-1 cells treated with 
5 χ 10~ 5 M cisplatin at various times, (b) CAT values 
were computed and are presented in histograms 
as described in Figure 1. 
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Figure 3 Induction of CAT activity by cisplatin and 
D17872 and D18506. (a) Chromatograms for representa­
tive CAT assays with extracts from SVTGHIV1-1 cells 
treated with 5 χ 10~ 5 M cisplatin and the antineoplastic 
compounds D18506 and D17872. (b) CAT values were 
computed and are presented in histograms as described 
in Figure 1. 
Effect of other ant i-neoplast ic 
c o m p o u n d s on HIV LTR act ivat ion 
Two other compounds with known antineoplastic 
properties—D17872, a benzylethylenediamine de­
rivative of cisplatin,10 and D18506, a hexadecyl-
phosphocholine compound 1 1—were employed at 
concentrations similar to that of cisplatin (5 X 1 0 - 5 
M) to test their effect on HIV LTR activation. As 
shown in Figure 3, only the D17872 compound 
activated the HIV LTR at 1.7-fold, much below the 
activation caused by cisplatin. 
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Figure 4. Cell proliferation in response to cisplatin at various 
times of exposure. 5 χ 103 exponentially growing SVTGHIV1-1 cells were 
plated in 96-well tissue culture clusters (costar) in Ham's SF12 medium 
containing 10% FCS in the presence of the indicated concentration of 
cisplatin. At the indicated times cell proliferation was measured using 
Mossman's rapid colorimetrie assay.9 
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Cisplatin toxicity 
The effect of cisplatin on SVTGHIV1-1 cells was 
measured by a rapid cell proliferation assay. 
SVTGHIV1-1 cells were exposed for various times 
(0, 24, 48, 72, 96, 120 h) at a range of concentrations 
of the drug (from 5 x 10" 7 M to 1 χ I O - 4 M 
(Figure 4). 
The same initial number of cells was used for 
each concentration. Toxicity was measured, using 
Mosmann's colorimetrie MTT assay. As seen in 
Figure 4, at the concentration where the cisplatin 
was most effective in stimulating the HIV LTR 
(5 X 10~ 5M) it was strongly inhibitory for cell 
proliferation. 
Discussion 
The human immunodeficiency virus LTR contains 
several defined regulatory domains.5 These can be 
«j·-12'13 or trans-acting sequences responding to 
cellular14 or viral13 gene products. 
In a previous study we have found that cisplatin 
at 5 x Ι Ο - 3 M concentrations stimulated by 22-fold 
the expression of the reporter CAT gene from the 
HIV LTR in rat fibroblasts.6 In the present study 
we have found that in human fibroblasts cisplatin 
enhances the HIV LTR although at a much lower 
level (2.2-fold) (Figure 1). Again, it is of interest 
that the effect of cisplatin is observed when cell 
proliferation is strongly suppressed (Figure 4). 
Since cisplatin potentiates the activity of HIV LTR 
as shown before in rat,6 and as shown here in 
human, fibroblasts we urged further caution when 
considering therapy including this compound in the 
treatment of AIDS patients carrying tumors. 
References 
1. Rosenberg B, Van Camp L, Trosko JE, Mansour VH. 
Platinum compounds a new class of potent antitumour 
agents. Nature 1969; 222: 385-386. 
2. Loehrer PJ, Einhorn LE. Cis-platin. Ann Internal Med 
1984; 100: 704-713. 
3. Roberts JJ, Thomson AJ. The mechanism of action of 
antitumour platinum compounds. Progress Nucl Acid Res 
1979; 22: 71-133. 
4. Cremer KJ, Spring SB, Gruber J. Role of human 
immunodeficiency virus type 1 and other acquired 
immunodeficiency disease syndrome. J Natl Cancer Inst 
1990; 82: 1016-1024. 
5. Hammazskjold M-L, Recosh D. The molecular biology of 
the human immunodeficiency virus. Biochim Biopbys Acta 
1989; 959: 269-280. 
6. Spandidos DA, Zoumpourlis V, Kotsinas A, Maurer HR, 
Patsilinacos P. Transcriptional activation of the human 
immunodeficiency virus long terminal repeat sequences by 
cis-platin. Genetic Anal Tecbn Appi (in press). 
7. Berger J, Hamber J, Hamber R, Geiger R, Cullen BR. 
Secreted placental alkaline phosphatase: a powerful new 
quantitative indicator of gene expression in eukaryotic 
cells. Gene 1988; 66: 1-10. 
8. Spandidos DA, Riggio M. Promoter and enhancer like 
activity at the 5'-end of normal and T24 Ha-ra.rl genes. 
FEBS Lett 1986; 203: 169-174. 
9. Mosmann T. Rapid colorimetrie assay for cellular growth 
and survival: application of proliferation and cytoxicitv 
assays. J Immunolog Met. 1983; 65: 55—63. 
10. Maurer HR, Echarti C, Voegeli R, Pohl J, Hilgard P. The 
antitumor activity of Dl7872 is associated with tumor cell 
differentiation. Cancer Chemoth Pharm (in press). 
11. Voegeli R, Echarti C, Maurer HR, et al. Selective activity 
of hexadecylphosphocholine against tumor cell in vitro is 
paralleled by its anti-tumor activity in vitro. Eur J Cancer 
Clin Oncology (in press). 
12. Kaufman JD, Valandra G, Roderiguez G, Bushar G, Giri 
C, Norcross MA. Phorbol ester enhances human 
immunodeficiency virus-promoted gene expression and 
acts on a repeated 10-base-pair functional enhancer 
element. Mot Cell Biol 1987; 7: 3759-3766. 
13. Rosen CA, Sodroski JG, Haseltine WA. The location of 
cis-acting regulatory sequences in the human Τ cell 
lymphotropic virus type III (HTLV-III/LAV) long 
terminal repeat. Cell 1985; 41 : 813-823. 
14. Spandidos DA, Yiagnisis M, Pintzas A. Human 
immunodeficiency virus long terminal repeat responds to 
transformation by the mutant T24 H-ras\ oncogene and it 
contains multiple AP-1 binding TPA-inducible consensus 
sequence elements. Anticancer Res 1989; 9: 383-386. 
15. Jakobovits A, Rosenthal A, Capon DJ. Trans-activation 
of HIV1-1 LTR-directed gene expression by tat requires 
protein kinase C. EMBO J 1990; 9: 1165-1170. 
(Received 2 August 1990; accepted 23 August 1990) 
58 
; 
